Life Science Today

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs.

Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Final Episode

This week, I have an announcement to make.

Find out more at
https://LifeScienceTodayPodcast.com


About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry. 

Sanofi/Takeda, UniQure & CSL, Fog Pharma, Merck + Imago

Vaccine hesitancy, the most expensive gene therapy in the world, a $178M series D, and a $1.3B buyout

Find out more at
https://LifeScienceTodayPodcast.com

Story References
Sanofi/Takeda
UniQure & CSL
Fog Pharma
Merck + Imago

About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry. 

Indivior + Opiant, Regeneron + CytomX, Rezo, Provention

A $145M opioid acquisition, biobucks for the holidays, a series A, and diabetes approvals

Find out more at
https://LifeScienceTodayPodcast.com

Story References
Indivior + Opiant
Regeneron + CytomX
Rezo
Prevention

About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry. 

Intellia, Regeneron, Viatris + Oyster Point

More CRISPR data, oncology wins, and a new player in ophthalmology

Find out more at
https://LifeScienceTodayPodcast.com

Story References
Intellia
Regeneron
Viatris + Oyster Point

About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry. 

Sumitovant + Myovant, Thermo Fisher + Binding Site Group, Astellas & Taysha, Agios, Vaxctye

Billion-dollar acquisitions, troubled waters for some biotech’s, and a prosperous outlook for others

Find out more at
https://LifeScienceTodayPodcast.com

Story References
Sumitovant + Myovant
Thermo Fisher + Binding Site Group
Astellas & Taysha
Agios
Vaxctye

About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry. 

FDA, AbbVie + DJS, Roche + Hookipa, Kyverna

Some statistically significant guidance, seed to acquisition, some biobucks, and the CART of the future.

Find out more at
https://LifeScienceTodayPodcast.com

Story References
FDA
AbbVie + DJS
Roche + Hookipa
Kyverna

About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry. 

Responses

About Instructor

If you'd like to comment on this course or lecture please Register or Login.

THIS CONTENT IS FOR

Registered Users

Please login or register to continue.